Clinical Trial: Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06806930) titled 'Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)' on Jan. 15.

Brief Summary: The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are:

1. How breast cancer responds to endocrine therapy given prior to surgery?

2. To predict tumor pre-operative endocrine prognostic index (PEPI) score for subjects enrolled in cohort B or C

Participants with early-stage breast cancer (Stage I-III) who are eligible for Neoadjuvant Endocrine Therapy (NET) will be...